1. Response to: ‘Statins in systemic lupus erythematosus’ by Abud-Mendoza
- Author
-
Jan Willem Cohen Tervaert, Tjeerd van Staa, and Hilda J. I. de Jong
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Statin ,medicine.drug_class ,Population ,Immunology ,Disease ,General Biochemistry, Genetics and Molecular Biology ,Cohort Studies ,Disease activity ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,immune system diseases ,Epidemiology ,Humans ,Lupus Erythematosus, Systemic ,Immunology and Allergy ,Medicine ,skin and connective tissue diseases ,Intensive care medicine ,Primary care database ,030203 arthritis & rheumatology ,business.industry ,Medical record ,Clinical Practice ,030104 developmental biology ,Research Design ,Statin therapy ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business - Abstract
It was with great interest that we read the correspondence of Abud-Mendoza1 on our recent paper in which we described a decreased risk of developing systemic lupus erythematosus (SLE) in statin users who continued their therapy for >1 year.2 We agree that prevention of cardiovascular disease in rheumatic diseases is of great importance.3 Whether statins decrease disease activity in SLE is, however, controversial since a recent meta-analysis of five controlled trials did not suggest any significant effect of statin therapy on Systemic Lupus Erythematosus Disease Activity Index.4 Unfortunately, in the UK’s Clinical Practice Research Datalink (CPRD)—an ongoing primary care database of anonymised medical records from general practitioners that was used in our study—no measurements for SLE activity before or after initiating statin therapy are available.2 We, however, do not think that statin …
- Published
- 2018
- Full Text
- View/download PDF